HAEVENCI
Live / Registered — Registered (as of 21 Mar 2023)
What this means for you
Registered since 21 Mar 2023. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 21 Mar 2029: the §8 declaration of use).
Record
- Serial number
- 97148166
- Registration number
- 7003866
- Mark type
- Word mark
- Filed
- 30 Nov 2021
- Published for opposition
- 03 Jan 2023
- Registered
- 21 Mar 2023
- Next maintenance filing
- §8 declaration of use, due by 21 Mar 2029 (grace period to 21 Sept 2029)
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE
Owner
- CSL Behring GmbH, Marburg, DE
- CSL Behring GmbH, Marburg, DE
- CSL Behring GmbH, Marburg, DE
Prosecution history
- 21 Mar 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Mar 2023 — REGISTERED-PRINCIPAL REGISTER
- 03 Jan 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Jan 2023 — PUBLISHED FOR OPPOSITION
- 14 Dec 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Dec 2022 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Nov 2022 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Nov 2022 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Nov 2022 — ASSIGNED TO LIE
- 21 Sept 2022 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Sept 2022 — NON-FINAL ACTION E-MAILED
- 08 Sept 2022 — NON-FINAL ACTION WRITTEN
- 08 Sept 2022 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Sept 2022 — NON-FINAL ACTION E-MAILED